Keyphrases
Clonal Hematopoiesis
100%
Epithelial Ovarian Cancer
28%
Clinical Outcomes
25%
Ovarian Cancer
19%
Tumor Protein p53 (TP53)
18%
Solid Tumors
16%
Ovarian Cancer Risk
14%
Hazard Ratio
14%
Myelodysplastic Syndrome
14%
Genome-wide Association Study
13%
Hematopoietic Stem Cells
12%
Tumor
12%
Overall Survival
11%
Clinical Presentation
11%
Genome Stability
11%
Hematological Malignancies
10%
Confidence Interval
10%
Cardiovascular Disease
10%
Susceptibility Loci
9%
Somatic mutation
9%
Single nucleotide Polymorphism
9%
Clonal Hematopoiesis of Indeterminate Potential
8%
Ovarian Cancer Survival
8%
Breast Cancer Susceptibility Gene 1 (BRCA1)
8%
Chemotherapy
8%
Myeloid Malignancies
8%
SNP
8%
Cardiovascular Risk
7%
Variant Calling
7%
Cancer Therapy
7%
Genomic Profiling
7%
Clear Cell Ovarian Carcinoma
7%
Thromboembolic Risk
7%
Human Spaceflight
7%
Attention Deficit Hyperactivity Disorder
7%
BRCA2
7%
Myeloid Neoplasms
6%
COVID-19
6%
ARID1A
6%
Clonal Expansion
6%
Patients with Cancer
5%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
5%
Aging
5%
Comorbidity
5%
Genetic Profile
5%
Mutation Analysis
5%
DSM-IV
5%
Meta-analysis
5%
Germ Cells
5%
Germline mutation
5%
Biochemistry, Genetics and Molecular Biology
Hematopoiesis
67%
Myeloid
19%
Genome-Wide Association Study
18%
Single Nucleotide Polymorphism
14%
Cancer Survival
13%
BRCA1
12%
Germ Cell
12%
Germline
12%
Overall Survival
11%
Allele
11%
Genomics
11%
Single-Nucleotide Polymorphism
10%
Genetics
10%
KRAS
8%
ARID1A
8%
Hematopoietic Cell
8%
Tamsulosin
8%
Germline Mutation
8%
Proteomics
7%
Candidate Gene
7%
BRCA2
7%
Immunity
7%
Somatic Mutation
6%
Gene Mutation
5%
STK11
5%
Genome Instability
5%
Next Generation Sequencing
5%
P53
5%
Gene Expression
5%
Medicine and Dentistry
Hematopoiesis
74%
Krukenberg Tumor
23%
Neoplasm
22%
Malignant Neoplasm
19%
Ovarian Cancer
18%
Hematopoietic Cell
11%
Myelodysplastic Syndrome
11%
Diseases
11%
Hematologic Malignancy
10%
Cardiovascular Disease
9%
Solid Malignant Neoplasm
9%
Cancer Susceptibility
8%
Genome Wide Association Study
8%
Single Nucleotide Polymorphism
8%
Somatic Mutation
7%
Clear Cell
7%
Cancer
7%
Clinical Trial
5%
Leukemia
5%
Cardiovascular Risk
5%
Medicine
5%